Eprosartan

Eprosartan
Clinical data
Trade namesTeveten
AHFS/Drugs.comMonograph
MedlinePlusa601237
License data
Pregnancy
category
  • AU: D
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • US: ℞-only
Pharmacokinetic data
Bioavailability15% (Eprosartan mesylate)
Metabolismnot metabolized
Elimination half-life5 to 9 hours
ExcretionKidney 10%, bile duct 90%
Identifiers
IUPAC name
  • 4-({2-Butyl-5-[2-carboxy-2-(thiophen-2-ylmethyl)eth-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H24N2O4S
Molar mass424.52 g·mol−1
3D model (JSmol)
SMILES
  • O=C(O)\C(=C\c1cnc(n1Cc2ccc(C(=O)O)cc2)CCCC)Cc3sccc3
InChI
  • InChI=1S/C23H24N2O4S/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27/h4-5,7-12,14H,2-3,6,13,15H2,1H3,(H,26,27)(H,28,29)/b18-12+ checkY
  • Key:OROAFUQRIXKEMV-LDADJPATSA-N checkY
  (verify)

Eprosartan, sold under the brand name Teveten among others, is an angiotensin II receptor antagonist used for the treatment of high blood pressure.[1]

Eprosartan is sometimes paired with hydrochlorothiazide.[2]

As with other angiotensin II receptor antagonists, eprosartan is generally better tolerated than enalapril (an ACE inhibitor), especially among the elderly.[3]

History

The compound came into the Abbott Laboratories cardiovascular pipeline with its acquisition of Kos Pharmaceuticals in 2006, which had licensed it, along with "a range of hypertensive treatments", from the Biovail Corporation.[4]

References

  1. ^ "Eprosartan mesylate- eprosartan mesylate tablet, film coated". DailyMed. Retrieved 7 June 2023.
  2. ^ "Teveten HCT- eprosartan mesylate and hydrochlorothiazide tablet". DailyMed. 3 January 2012. Retrieved 7 June 2023.
  3. ^ Ruilope L, Jäger B, Prichard B (2001). "Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial". Blood Press. 10 (4): 223–9. doi:10.1080/08037050152669747. PMID 11800061. S2CID 13063704.
  4. ^ Anon., 2006, Abbott Laboratories: Kos Pharmaceuticals a wise buy, Datamonitor ResearchStore (online), November 8, 2006, see [1], accessed 29 January 2015.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.